Yuping P. Li

Nanbaixiang Street
Wenzhou, 325000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 102 publications

Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Chest

Published: January 20, 2026

Cadmium dominates urinary heavy metal mixtures associated with COPD risk: Integrative evidence from NHANES, network pharmacology, and experimental validation.

Cadmium dominates urinary heavy metal mixtures associated with COPD risk: Integrative evidence from NHANES, network pharmacology, and experimental validation.

Journal: Ecotoxicology and environmental safety

Published: November 17, 2025

Corrigendum to "Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation" [Int. Immunopharmacol. 164 (2025) 115396].

Corrigendum to "Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation" [Int. Immunopharmacol. 164 (2025) 115396].

Journal: International immunopharmacology

Published: September 07, 2025

Antibiotic exposure impairs the efficacy of first-line chemoimmunotherapy in non-small cell lung cancer through the regulation of gut microbiome and bile acid metabolism.

Antibiotic exposure impairs the efficacy of first-line chemoimmunotherapy in non-small cell lung cancer through the regulation of gut microbiome and bile acid metabolism.

Journal: Precision clinical medicine

Published: August 19, 2025

Coptisine mitigates acute lung injury by alleviating ferroptosis through the PI3K/AKT/Nrf2 pathway.

Coptisine mitigates acute lung injury by alleviating ferroptosis through the PI3K/AKT/Nrf2 pathway.

Journal: Journal of ethnopharmacology

Published: June 10, 2025

Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation.

Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation.

Journal: International immunopharmacology

Published: April 15, 2025

Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC.

Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC.

Journal: Journal of translational medicine

Published: January 10, 2025

Comparative analysis of six nutritional scores in predicting prognosis of COVID-19 patients.

Comparative analysis of six nutritional scores in predicting prognosis of COVID-19 patients.

Journal: Frontiers in nutrition

Published: September 24, 2024

Lysophosphatidylcholine 14:0 Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Protecting Alveolar Epithelial Barrier by Activation of Nrf2/HO-1 Pathway.

Lysophosphatidylcholine 14:0 Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Protecting Alveolar Epithelial Barrier by Activation of Nrf2/HO-1 Pathway.

Journal: Journal of inflammation research

Published: September 08, 2024

An enhancing diagnostic pulmonary diseases diagnostic method for differentiating talaromycosis from tuberculosis.

An enhancing diagnostic pulmonary diseases diagnostic method for differentiating talaromycosis from tuberculosis.

Journal: iScience

Published: August 04, 2024

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer.

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer.

Journal: The Lancet regional health. Western Pacific

Published: April 16, 2024

3-methyladenine ameliorates acute lung injury by inhibiting oxidative damage and apoptosis.

3-methyladenine ameliorates acute lung injury by inhibiting oxidative damage and apoptosis.

Journal: Heliyon

Published: January 04, 2024

Showing 1-12 of 102

Last Updated: 09/26/2026